Fate Therapeutics Inc. diskutieren
Fate Therapeutics Inc.
WKN: A1W50M / Symbol: FATE / Name: Fate / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
2,22 €
-0,73 %
Buy Fate Therapeutics Inc.
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $10.00 price target on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Mizuho from $12.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Barclays PLC from $6.00 to $10.00. They now have an "overweight" rating on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Bank of America Co. from $2.00 to $6.00. They now have an "underperform" rating on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $6.00 price target on the stock, up previously from $4.00.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Barclays PLC from $10.00 to $2.00. They now have an "overweight" rating on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $5.00.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics (FATE) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics (FATE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics (FATE) had its "outperform" rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.
Ratings data for FATE provided by MarketBeat
Fate Therapeutics (FATE) had its "overweight" rating reaffirmed by Piper Sandler.
Ratings data for FATE provided by MarketBeat
Neueste Beiträge
Needham___Company_LL in Plexus Corp. diskutieren